Precision Biosensor

Precision Biosensor Equity Ratio

The Equity Ratio of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is 61.74 %. In the previous year, Equity Ratio was 49.38 % — a change of 25.02% (higher).

Equity Ratio

61.74 %

YoY

25.02%

Last updated:

Equity Ratio of Precision Biosensor is 2025 61.74 % . Equity Ratio of Precision Biosensor was 2024 49.38 % . It decreases by 25.02% higher compared to the previous year.

The Precision Biosensor Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
-12.24 KRW
Jan 1, 2019
53.26 KRW
Jan 1, 2020
88.04 KRW
Jan 1, 2021
68.83 KRW
Jan 1, 2022
56.56 KRW
Jan 1, 2023
51.26 KRW
Jan 1, 2024
49.38 KRW
Jan 1, 2025
61.74 KRW
The Precision Biosensor Equity Ratio history
YEAREquity RatioYoY
61.74 %+25.02%
49.38 %-3.67%
51.26 %-9.37%
56.56 %-17.83%
68.83 %-21.81%
88.04 %+65.30%
53.26 %-535.17%
-12.24 %-174.13%
16.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Equity Ratio of Precision Biosensor is 61.74 % in 2025.

Equity Ratio of Precision Biosensor changed from 49.38 % to 61.74 %, representing a 25.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Precision Biosensor with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Precision Biosensor

All Key Metrics — Precision Biosensor